NEWS AND VIEWS
Hygieia adds Metro Detroit Endocrinology Center as clinical partner for its d-Nav® Insulin Management Program
New partnership expands availability of d-Nav program for underserved Livonia, Mich., August 30, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav® network and makes autonomous insulin therapy service available for an underserved population. The unique…
Hygieia announces new CPT codes for autonomous insulin dose titration
Livonia, Mich., July 26, 2022 – Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieia’s d-Nav® Technology. d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations…
Hygieia Advances its Global Business Development Activities with d-Nav® Program in Israel
Livonia, Michigan, June 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally. d-Nav…
Hygieia Launches d-Nav® Clinical Partnership Program at AACE Annual Meeting
SAN DIEGO, Calif.–(BUSINESS WIRE)–Hygieia, a digital therapeutics company, today announced the official launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes. The d-Nav Clinical Partnership Program is turnkey. It provides patients with access to d-Nav autonomous insulin dose technology and a clinical support team. For clinical partners, the d-Nav…
Digital insulin management company Hygieia closes on $17 million Series B investment round
Funding will enable expansion of company’s AI-driven d-Nav® technology, which automates real-time insulin dose recommendations for people with type 2 diabetes LIVONIA, Mich., December 2, 2021 – Hygieia, a digital health company for insulin management, has closed on an initial $17 million Series B investment round, led by Israeli venture capital firm Firstime Ventures, and with participation from…
The d-Nav® Program Featured on WXYZ TV
Two thirds of people who take insulin for type 2 diabetes do not have their blood sugar in the desired range. Andrea Isom from WXYZ TV 7 in Detroit talked with Hygieia CEO and Co-Founder Eran Bashan and d-Nav patient Marty Cook to find out how the d-Nav technology helps Marty, and potentially millions of…
JOIN OUR NETWORK
Discover the latest insights and views about type 2 diabetes.
RESEARCH & STUDIES
Explore d-Nav studies, peer reviewed and white papers.
PRESS INQUIRIES
Reinheimer PR & Marketing